References
[1] S. Su et al. , “Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses,” Trends in Microbiology , vol. 24, no. 6. 2016, doi: 10.1016/j.tim.2016.03.003.
[2] World Health Organization, “World Health Organization. Coronavirus disease 2019 (COVID-19),” Situation Report, 32. , vol. 2019, no. February. 2020.
[3] M. Aboughdir, T. Kirwin, A. A. Khader, and B. Wang, “Prognostic value of cardiovascular biomarkers in COVID-19: A review,”Viruses , vol. 12, no. 5. 2020, doi: 10.3390/v12050527.
[4] C. Danwang, F. T. Endomba, J. R. Nkeck, D. L. A. Wouna, A. Robert, and J. J. Noubiap, “A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19),”Biomarker Research , vol. 8, no. 1. 2020, doi: 10.1186/s40364-020-00217-0.
[5] J. L. Nguyen, W. Yang, K. Ito, T. D. Matte, J. Shaman, and P. L. Kinney, “Seasonal influenza infections and cardiovascular disease mortality,” JAMA Cardiol. , vol. 1, no. 3, 2016, doi: 10.1001/jamacardio.2016.0433.
[6] V. F. Corrales-Medina et al. , “Cardiac complications in patients with community-acquired pneumonia: A systematic review and meta-analysis of observational studies,” PLoS Medicine , vol. 8, no. 6. 2011, doi: 10.1371/journal.pmed.1001048.
[7] T. Alhogbani, “Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus,” Ann. Saudi Med. , vol. 36, no. 1, 2016, doi: 10.5144/0256-4947.2016.78.
[8] T. Guo et al. , “Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19),”JAMA Cardiol. , vol. 5, no. 7, 2020, doi: 10.1001/jamacardio.2020.1017.
[9] T. Chen et al. , “Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study,”BMJ , vol. 368, 2020, doi: 10.1136/bmj.m1091.
[10] C. Yang et al. , “Myocardial injury and risk factors for mortality in patients with COVID-19 pneumonia,” Int. J. Cardiol. , vol. 326, 2021, doi: 10.1016/j.ijcard.2020.09.048.
[11] F. Zhou et al. , “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” Lancet , vol. 395, no. 10229, 2020, doi: 10.1016/S0140-6736(20)30566-3.
[12] H. Han et al. , “Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China,”J. Med. Virol. , vol. 92, no. 7, 2020, doi: 10.1002/jmv.25809.
[13] R. M. Inciardi et al. , “Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy,” Eur. Heart J. , vol. 41, no. 19, 2020, doi: 10.1093/eurheartj/ehaa388.
[14] C. M. Lombardi et al. , “Association of Troponin Levels with Mortality in Italian Patients Hospitalized with Coronavirus Disease 2019: Results of a Multicenter Study,” JAMA Cardiol. , vol. 5, no. 11, 2020, doi: 10.1001/jamacardio.2020.3538.
[15] G. G. Stefanini et al. , “Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19,” Heart , vol. 106, no. 19, 2020, doi: 10.1136/heartjnl-2020-317322.
[16] T. J. Poterucha et al. , “Admission cardiac diagnostic testing with electrocardiography and troponin measurement prognosticates increased 30-day mortality in COVID-19,” J. Am. Heart Assoc. , vol. 10, no. 1, 2021, doi: 10.1161/JAHA.120.018476.
[17] S. Aggarwal, N. Garcia-Telles, G. Aggarwal, C. Lavie, G. Lippi, and B. M. Henry, “Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States,” Diagnosis , vol. 7, no. 2, 2020, doi: 10.1515/dx-2020-0046.
[18] S. Nathisuwan and R. L. Talbert, “A review of vasopeptidase inhibitors: A new modality in the treatment of hypertension and chronic heart failure,” Pharmacotherapy . 2002, doi: 10.1592/phco.22.1.27.33502.
[19] E. R. Levin and H. J. L. Frank, “Natriuretic peptides inhibit rat astroglial proliferation: Mediation by C receptor,” Am. J. Physiol. - Regul. Integr. Comp. Physiol. , vol. 261, no. 2 30-2, 1991, doi: 10.1152/ajpregu.1991.261.2.r453.
[20] L. S. Marcus et al. , “Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial,” Circulation , 1996, doi: 10.1161/01.CIR.94.12.3184.
[21] T. Omland, “Clinical and laboratory diagnostics of cardiovascular disease: Focus on natriuretic peptides and cardiac ischemia,” in Scandinavian Journal of Clinical and Laboratory Investigation, Supplement , 2005, vol. 65, no. 240, doi: 10.1080/00365510500236077.
[22] J. Caro-Codón et al. , “Characterization of NT-proBNP in a large cohort of COVID-19 patients,” Eur. J. Heart Fail. , 2021, doi: 10.1002/ejhf.2095.
[23] S. Sorrentino et al. , “B-Type Natriuretic Peptide as Biomarker of COVID-19 Disease Severity—A Meta-Analysis,” J. Clin. Med. , vol. 9, no. 9, 2020, doi: 10.3390/jcm9092957.
[24] L. Gao et al. , “Prognostic value of NT-proBNP in patients with severe COVID-19,” Respir. Res. , vol. 21, no. 1, 2020, doi: 10.1186/s12931-020-01352-w.
[25] D. W. Park et al. , “Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention,” Eur. Heart J. , vol. 34, no. 22, 2013, doi: 10.1093/eurheartj/eht048.
[26] J. Bao, C. Li, K. Zhang, H. Kang, W. Chen, and B. Gu, “Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19,” Clin. Chim. Acta , vol. 509, 2020, doi: 10.1016/j.cca.2020.06.009.
[27] L. Shi, Y. Wang, Y. Wang, G. Duan, and H. Yang, “Meta-Analysis of Relation of Creatine kinase-MB to Risk of Mortality in Coronavirus Disease 2019 Patients,” Journal of Cleaner Production . 2020, doi: 10.1016/j.amjcard.2020.06.004.
[28] S. Babapoor-Farrokhran, D. Gill, J. Walker, R. T. Rasekhi, B. Bozorgnia, and A. Amanullah, “Myocardial injury and COVID-19: Possible mechanisms,” Life Sci. , vol. 253, 2020, doi: 10.1016/j.lfs.2020.117723.
[29] M. Boukhris et al. , “Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective,” Canadian Journal of Cardiology , vol. 36, no. 7. 2020, doi: 10.1016/j.cjca.2020.05.018.
[30] J. W. Li et al. , “The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis,” Progress in Cardiovascular Diseases , vol. 63, no. 4. 2020, doi: 10.1016/j.pcad.2020.04.008.
[31] S. Shi et al. , “Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China,”JAMA Cardiol. , vol. 5, no. 7, 2020, doi: 10.1001/jamacardio.2020.0950.
[32] D. Wang et al. , “Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China,” JAMA - J. Am. Med. Assoc. , vol. 323, no. 11, 2020, doi: 10.1001/jama.2020.1585.
[33] Z. Xu et al. , “Pathological findings of COVID-19 associated with acute respiratory distress syndrome,” Lancet Respir. Med. , vol. 8, no. 4, 2020, doi: 10.1016/S2213-2600(20)30076-X.
[34] R. O. Bonow, G. C. Fonarow, P. T. O’Gara, and C. W. Yancy, “Association of Coronavirus Disease 2019 (COVID-19) with Myocardial Injury and Mortality,” JAMA Cardiology , vol. 5, no. 7. 2020, doi: 10.1001/jamacardio.2020.1105.
[35] J. C. Kwong et al. , “Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection,” N. Engl. J. Med. , vol. 378, no. 4, 2018, doi: 10.1056/nejmoa1702090.
[36] M. Madjid et al. , “Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: Results from 8 years of autopsies in 34 892 subjects,” Eur. Heart J. , vol. 28, no. 10, 2007, doi: 10.1093/eurheartj/ehm035.
[37] R. M. Inciardi et al. , “Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19),” JAMA Cardiol. , vol. 5, no. 7, 2020, doi: 10.1001/jamacardio.2020.1096.
[38] D. C. Fajgenbaum and C. H. June, “Cytokine Storm,” N. Engl. J. Med. , vol. 383, no. 23, 2020, doi: 10.1056/nejmra2026131.
[39] G. Lippi, C. J. Lavie, and F. Sanchis-Gomar, “Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis,” Progress in Cardiovascular Diseases , vol. 63, no. 3. 2020, doi: 10.1016/j.pcad.2020.03.001.
[40] R. Pranata, I. Huang, A. A. Lukito, and S. B. Raharjo, “Elevated N-Terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: Systematic review and meta-Analysis,” Postgraduate Medical Journal , vol. 96, no. 1137. 2020, doi: 10.1136/postgradmedj-2020-137884.
[41] T. Dalia et al. , “Impact of congestive heart failure and role of cardiac biomarkers in COVID-19 patients: A systematic review and meta-analysis,” Indian Heart J. , vol. 73, no. 1, 2021, doi: 10.1016/j.ihj.2020.12.002.
[42] S. Wan et al. , “Clinical features and treatment of COVID-19 patients in northeast Chongqing,” J. Med. Virol. , vol. 92, no. 7, 2020, doi: 10.1002/jmv.25783.
[43] C. Liu and Y. Wang, “Discussion on the application of febrile disease theory to the diagnosis and treatment of novel coronavirus pneumonia,” Open Access Online-First Publ Res Pap COVID-19 , 2020.
[44] J. F. Wei et al. , “Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis,” Heart , vol. 106, no. 15, 2020, doi: 10.1136/heartjnl-2020-317007.
[45] S. Ghio et al. , “Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy,” Intern. Emerg. Med. , vol. 15, no. 8, 2020, doi: 10.1007/s11739-020-02493-y.